MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib.
Yip C, Foidart P, Somja J, Truong A, Lienard M, Feyereisen E, Schroeder H, Gofflot S, Donneau AF, Collignon J, Delvenne P, Sounni NE, Jerusalem G, Noël A.
Yip C, et al. Among authors: donneau af.
Br J Cancer. 2017 Mar 14;116(6):742-751. doi: 10.1038/bjc.2017.23. Epub 2017 Feb 14.
Br J Cancer. 2017.
PMID: 28196064
Free PMC article.